Skip to main content

Point-of-care tests to revolutionise the clinical management of patients infected by Hepatitis C virus

Objective

Point-of-care (PoC) medical devices have the potential to revolutionise clinical practice. SMEs within our Consortium (Epistem & Biosurfit) have developed genetic and protein PoC devices to deliver on this promise. Results from these enabling technologies will be integrated using novel bioinformatics tools and algorithms (Qlucore) allowing for bed-side analysis. This integrated genetic-protein approach will exploit recent biomarker discoveries from the FP7 project SPHINX, to improve the management of hepatitis C virus (HCV) infected patients. We will focus on two public health problems: (i) addressing the need to predict, pre-treatment, individuals in resource poor countries (e.g. Egypt) who will benefit from conventional treatment; and (ii) helping to limit treatment costs globally, where new therapies for HCV are anticipated to significantly increase health care expenditures. The predicitve biomarkers are ready for immediate implementation and will greatly improve HCV patient management issues such as decision to treat, selection of therapy, and response-guided monitoring. The predictive power of the SPHINX biomarkers are reliant upon the combination of genetic and protein data. Highlighting the innovative aspect of our proposed work, no clinical algorithms have taken advantage of such a combined genetic / protein biomarker approach for diagnostic tests. To realise this vision, Qlucore will establish patient population-based algorithms that integrate the PoC data on a mobile application, thus facilitating immediate interpretation by physicians. Together, our Consortium will boost prior FP7 discoveries and deliver an integrated platform for predictive and prognostic applications. The associated SMEs will expand their portfolio, but more importantly, our consortium will forge a lasting partnership, formalised by the creation of a new corporation that will have the freedom to market and exploit our collective results.

Call for proposal

FP7-HEALTH-2013-INNOVATION-2
See other projects for this call

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Address
Rue De Tolbiac 101
75654 Paris
France
Activity type
Research Organisations
EU contribution
€ 2 063 193
Administrative Contact
Laurie Louis-Joseph (Ms.)

Participants (4)

INSERM TRANSFERT SA
France
EU contribution
€ 220 120
Address
Rue Watt 7
75013 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jerome Weinbach (Dr.)
EPISTEM LTD
United Kingdom
EU contribution
€ 1 459 738
Address
Grafton Street Incubator Bldg 48
M13 9XX Manchester
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Ben Reed (Dr.)
BIOSURFIT SA
Portugal
EU contribution
€ 1 393 000
Address
Centro Empresarial De Aveiro
3810 744 Aveiro
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Daniel Neves (Dr.)
QLUCORE AB
Sweden
EU contribution
€ 855 375
Address
Scheelevagen 17
223 70 Lund
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Carl-Johan Ivarsson (Mr.)